Clinical Trial: An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Study Status: Approved for marketing
Recruit Status: Approved for marketing
Study Type: Expanded Access
Official Title: An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy (ACCESS)
Brief Summary: The present study is planned as an expanded treatment protocol to provide acromegalic patients for whom medical therapy is appropriate access to pasireotide LAR while regulatory approval for pasireotide is sought.
Detailed Summary:
Sponsor: Novartis Pharmaceuticals
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: November 20, 2013
Date Started:
Date Completion:
Last Updated: December 26, 2015
Last Verified: December 2015